United States · Business magazines · Inc.

This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent

Published by Inc. · United States 1 h ago

A groundbreaking phase 3 clinical trial reveals that a personalized mRNA vaccine from Merck and Moderna significantly cuts the risk of melanoma returning.

Read the full article on Inc. Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.inc.com)

Also worth reading

Quartz

12 things to do in Istanbul, from Hagia Sophia to a Bosphorus ferry

Fortune

A $44 million superhero horror film won the box office this weekend. A $7 million documentary came within $5 million of beating it

Kiplinger

Stocks Start a Big Week With Solid Gains: Stock Market Today

Fox Business

Microsoft offers voluntary buyouts to 60,000 employees as tech giant reshapes its workforce

Fast Company

Entrepreneurship might be the key to a longer life

Entrepreneur